BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18051801)

  • 1. [Clinical study of the urinary tract infections due to Escherichia coli harboring extended-spectrum beta lactamase].
    Hori J; Yamaguchi S; Osanai H; Kinebuchi T; Usami K; Takahashi N; Ishii Y
    Hinyokika Kiyo; 2007 Nov; 53(11):777-82. PubMed ID: 18051801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
    Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S
    Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C
    Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli.
    Rooney PJ; O'Leary MC; Loughrey AC; McCalmont M; Smyth B; Donaghy P; Badri M; Woodford N; Karisik E; Livermore DM
    J Antimicrob Chemother; 2009 Sep; 64(3):635-41. PubMed ID: 19549667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria.
    Suankratay C; Jutivorakool K; Jirajariyavej S
    J Med Assoc Thai; 2008 Aug; 91(8):1172-81. PubMed ID: 18788687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran.
    Mehrgan H; Rahbar M
    Int J Antimicrob Agents; 2008 Feb; 31(2):147-51. PubMed ID: 18060745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
    Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
    Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of drug-resistant Escherichia coli in patients with complicated cystitis: analysis of risk factors.
    Shigehara K; Uchibayashi T; Maeda E; Namiki M
    Int J Urol; 2009 Oct; 16(10):808-12. PubMed ID: 19659550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Etiologic agents and risk factors in nosocomial urinary tract infections].
    Akkoyun S; Kuloğlu F; Tokuç B
    Mikrobiyol Bul; 2008 Apr; 42(2):245-54. PubMed ID: 18697422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
    J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of extended spectrum beta-lactamases producing clinical isolates from patients of urinary tract infection in a tertiary care hospital in Delhi.
    Malhotra VL; Khandpur N; Dass A; Mehta G
    J Commun Dis; 2008 Dec; 40(4):269-72. PubMed ID: 19579719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of an epidemic of an extended spectrum beta-lactamase producing Escherichia coli in a geriatrics department].
    Cukier L; Lutzler P; Bizien A; Avril JL
    Pathol Biol (Paris); 1999 May; 47(5):440-4. PubMed ID: 10418015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.